Gilead Sciences, Inc. (NASDAQ:GILD) - Leerink Swann boosted their Q4 2017 earnings estimates for shares of Gilead Sciences in a report released on Monday. Leerink Swann analyst G. Porges now expects that the biopharmaceutical company will post earnings per share of $2.09 for the quarter, up from their prior estimate of $1.94. Leerink Swann has a “Market Perform” rating on the stock. Leerink Swann also issued estimates for Gilead Sciences’ FY2021 earnings at $8.10 EPS.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.18 by $0.02. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.66 billion. WARNING: This piece was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/07/20/q4-2017-eps-estimates-for-gilead-sciences-inc-increased-by-leerink-swann-nasdaqgild.html.
Other analysts have also recently issued research reports about the stock. Jefferies Group LLC reiterated a “hold” rating and issued a $80.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 11th. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price target for the company. in a research note on Tuesday, April 25th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Barclays PLC reiterated an “overweight” rating and issued a $85.00 price target on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $76.00 price target (up previously from $75.00) on shares of Gilead Sciences in a research note on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $80.24.
Shares of Gilead Sciences (GILD) traded up 0.5087% during midday trading on Wednesday, hitting $73.0899. 3,410,643 shares of the company’s stock were exchanged. The company has a 50-day moving average of $68.08 and a 200-day moving average of $68.59. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $88.85. The firm has a market cap of $95.51 billion, a price-to-earnings ratio of 7.7246 and a beta of 1.21.
Institutional investors have recently bought and sold shares of the company. Hall Laurie J Trustee increased its position in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares in the last quarter. Cable Hill Partners LLC increased its position in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. increased its position in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares in the last quarter. Finally, Penserra Capital Management LLC increased its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares in the last quarter. 74.03% of the stock is currently owned by hedge funds and other institutional investors.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the transaction, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the transaction, the executive vice president now directly owns 102,988 shares in the company, valued at $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold a total of 88,276 shares of company stock valued at $6,230,610 in the last 90 days. 1.30% of the stock is currently owned by company insiders.
The firm also recently declared a quarterly dividend, which was paid on Thursday, June 29th. Shareholders of record on Friday, June 16th were paid a dividend of $0.52 per share. The ex-dividend date of this dividend was Wednesday, June 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.86%. Gilead Sciences’s dividend payout ratio (DPR) is presently 21.99%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
